ReviewMolecular biology reports2026
Adropin signaling pathways in metabolic and non-metabolic disorders.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Adropin is a secreted 76-amino-acid peptide encoded by the energy homeostasis-associated gene ENHO. First identified in 2008 as a nutrient-responsive signal linking macronutrient intake with energy balance and lipid metabolism, it is now recognized as a pleiotropic hormone with actions extending well beyond classical metabolic tissues. Circulating adropin is typically reduced in obesity, type 2 diabetes, metabolic dysfunction-associated steatotic liver disease, atherosclerosis, heart failure, cognitive aging, and several fibrotic and reproductive disorders. However, diabetic kidney disease and some acute stress states show the opposite pattern. Two cell-surface partners, the orphan G-protein-coupled receptor GPR19 and the GPI-anchored neuronal protein NB-3/CNTN6, initiate overlapping but tissue-specific cascades: AMPK/ACC, PI3K/Akt/eNOS, GPR19/MAPK/PDK4, Notch1/Hes1, and TGF-β/GLI1. Through these pathways, adropin improves insulin action and mitochondrial fuel selection, increases endothelial nitric oxide bioavailability, restrains vascular remodeling, preserves blood-brain barrier integrity, and represses fibroblast activation. This review (i) separates metabolic from non-metabolic disease evidence, (ii) introduces an explicit evidence map distinguishing direct evidence, indirect evidence, and genuine controversy for every receptor and pathway, (iii) adds dedicated coverage of central feeding control, calcium-handling dysregulation in coronary disease, TGF-β/GLI1 signaling, biomarker interpretation, and translational pharmacology, and (iv) argues that progress now depends on receptor definition, assay harmonization, and delivery chemistry rather than on further disease associations. Remaining barriers include peptide instability, blood-brain-barrier delivery, non-standardized immunoassays, incomplete receptor pharmacology, and a narrow or bidirectional therapeutic window in kidney injury and tumor immunity.
Indexed as
Identifiers
42859240What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.